ADVISORY, April 7, 2014 (GLOBE NEWSWIRE) --
In celebration of the one-year anniversary of its initial public offering (IPO), Tetraphase Pharmaceuticals, Inc. [TTPH], a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, will visit the NASDAQ MarketSite in Times Square.In honor of the occasion, Guy Macdonald, President and Chief Executive Officer will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Tuesday, April 8, 2014 – 3:45 p.m. to 4:00 p.m. ET Tetraphase Pharmaceuticals, Inc. Contact: Jennifer LaVin (617) 715-3591 (office) (781) 718-7037 (cell) email@example.com NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ. For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx. For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/ Webcast: A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx. Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice. About Tetraphase Pharmaceuticals, Inc. [TTPH]: Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy. The safety and efficacy of eravacycline is currently being studied in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.